Journal
IMMUNITY
Volume 39, Issue 2, Pages 357-371Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2013.07.018
Keywords
-
Categories
Funding
- Collaborative Research Center (DFG) [SFB796]
- ERC [PAS_241506]
- Interdisciplinary Center for Clinical Research (IZKF)
- ELAN program of the University Medical Center of Erlangen
- Medical Research Council [MC_U105178805] Funding Source: researchfish
- MRC [MC_U105178805] Funding Source: UKRI
Ask authors/readers for more resources
Liver fibrosis is a consequence of chronic liver diseases and thus a major cause of mortality and morbidity. Clinical evidence and animal studies suggest that local tissue homeostasis is disturbed due to immunological responses to chronic hepatocellular stress. Poorly defined stress-associated inflammatory networks are thought to mediate gradual accumulation of extracellular-matrix components, ultimately leading to fibrosis and liver failure. Here we have reported that hepatic expression of interleukin-33 (IL-33) was both required and sufficient for severe hepatic fibrosis in vivo. We have demonstrated that IL-33's profibrotic effects related to activation and expansion of liver resident innate lymphoid cells (ILC2). We identified ILC2-derived IL-13, acting through type-II IL-4 receptor-dependent signaling via the transcription factor STAT6 and hepatic stellate-cell activation, as a critical downstream cytokine of IL-33-dependent pathologic tissue remodeling and fibrosis. Our data reveal key immunological networks implicated in hepatic fibrosis and support the concept of modulation of IL-33 bioactivity for therapeutic purposes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available